Simply Wall St.
Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge?
📊
AI Sentiment
Positive
7/10
- Home
- MDGL
as of 03-13-2026 10:20am EST
$440.61
+$1.88
+0.43%
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 10.0B | IPO Year: | 2005 |
| Target Price: | $674.45 | AVG Volume (30 days): | 327.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.85 | EPS Growth: | 41.32 |
| 52 Week Low/High: | $265.00 - $615.00 | Next Earning Date: | 05-19-2026 |
| Revenue: | $180,133,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 58.7% | Revenue Growth (next year): | 46.88% |
| P/E Ratio: | -34.19 | Index: | N/A |
| Free Cash Flow: | -190020000.0 | FCF Growth: | N/A |
AI-Powered MDGL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 15 hours ago
AI Recommendation
hold
Model Accuracy: 75.00%
75.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
Taub Rebecca
Sell
Director
MDGL Mar 6, 2026
Avg Cost/Share
$431.94
Shares
491
Total Value
$212,082.54
Owned After
452,213
SEC Form 4
Huntsman Carole
Sell
Chief Commercial Officer
MDGL Mar 6, 2026
Avg Cost/Share
$431.94
Shares
419
Total Value
$180,982.86
Owned After
12,692
SEC Form 4
Kelley Shannon T
Sell
General Counsel
MDGL Mar 6, 2026
Avg Cost/Share
$431.94
Shares
360
Total Value
$155,498.40
Owned After
12,138
SEC Form 4
Dier Mardi
Sell
EVP and CFO
MDGL Mar 2, 2026
Avg Cost/Share
$427.21
Shares
1,183
Total Value
$505,389.43
Owned After
9,257
SEC Form 4
Taub Rebecca
Sell
Director
MDGL Jan 26, 2026
Avg Cost/Share
$492.42
Shares
647
Total Value
$318,595.74
Owned After
452,213
SEC Form 4
Huntsman Carole
Sell
Chief Commercial Officer
MDGL Jan 26, 2026
Avg Cost/Share
$493.51
Shares
910
Total Value
$449,339.10
Owned After
12,692
Sibold William John
Sell
President and CEO
MDGL Jan 26, 2026
Avg Cost/Share
$492.42
Shares
1,577
Total Value
$776,546.34
Owned After
148,497
SEC Form 4
Taub Rebecca
Sell
Director
MDGL Jan 20, 2026
Avg Cost/Share
$490.77
Shares
2,238
Total Value
$1,098,343.26
Owned After
452,213
SEC Form 4
Kelley Shannon T
Sell
General Counsel
MDGL Jan 20, 2026
Avg Cost/Share
$496.09
Shares
692
Total Value
$344,173.11
Owned After
12,138
Taub Rebecca
Sell
Director
MDGL Jan 9, 2026
Avg Cost/Share
$528.25
Shares
18,650
Total Value
$9,749,392.08
Owned After
452,213
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Taub Rebecca | MDGL | Director | Mar 6, 2026 | Sell | $431.94 | 491 | $212,082.54 | 452,213 | |
| Huntsman Carole | MDGL | Chief Commercial Officer | Mar 6, 2026 | Sell | $431.94 | 419 | $180,982.86 | 12,692 | |
| Kelley Shannon T | MDGL | General Counsel | Mar 6, 2026 | Sell | $431.94 | 360 | $155,498.40 | 12,138 | |
| Dier Mardi | MDGL | EVP and CFO | Mar 2, 2026 | Sell | $427.21 | 1,183 | $505,389.43 | 9,257 | |
| Taub Rebecca | MDGL | Director | Jan 26, 2026 | Sell | $492.42 | 647 | $318,595.74 | 452,213 | |
| Huntsman Carole | MDGL | Chief Commercial Officer | Jan 26, 2026 | Sell | $493.51 | 910 | $449,339.10 | 12,692 | |
| Sibold William John | MDGL | President and CEO | Jan 26, 2026 | Sell | $492.42 | 1,577 | $776,546.34 | 148,497 | |
| Taub Rebecca | MDGL | Director | Jan 20, 2026 | Sell | $490.77 | 2,238 | $1,098,343.26 | 452,213 | |
| Kelley Shannon T | MDGL | General Counsel | Jan 20, 2026 | Sell | $496.09 | 692 | $344,173.11 | 12,138 | |
| Taub Rebecca | MDGL | Director | Jan 9, 2026 | Sell | $528.25 | 18,650 | $9,749,392.08 | 452,213 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 19, 2026 · 72% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 19, 2026 · 72% conf.
AI Prediction SELL
1D
-1.23%
$431.50
5D
-3.91%
$419.77
20D
+1.23%
$442.24
Price: $436.87 Prob +5D: 14% AUC: 1.000
0001628280-26-009476
mdgl-202602190001157601FALSE00011576012026-02-192026-02-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026
MADRIGAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3327704-3508648 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428 (Address of principal executive offices)(Zip Code)
(267) 824-2827 Registrant’s telephone number, including area code (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per ShareMDGLThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On February 19, 2026, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter and year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number Description
99.1Press Release Dated February 19, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MADRIGAL PHARMACEUTICALS, INC.
By:/s/ Mardi Dier Name: Mardi Dier Title: Executive Vice President and Chief Financial Officer Date: February 19, 2026
3
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 4, 2025
0001628280-25-048525
mdgl-202511040001157601FALSE00011576012025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025
MADRIGAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3327704-3508648 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428 (Address of principal executive offices)(Zip Code)
(267) 824-2827 Registrant’s telephone number, including area code (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per ShareMDGLThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number Description
99.1Press Release Dated November 4, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MADRIGAL PHARMACEUTICALS, INC.
By:/s/ Mardi Dier Name: Mardi Dier Title: Executive Vice President and Chief Financial Officer Date: November 4, 2025
3
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0001628280-25-037596
mdgl-202508050001157601FALSE00011576012025-08-052025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025
MADRIGAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3327704-3508648 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428 (Address of principal executive offices)(Zip Code)
(267) 824-2827 Registrant’s telephone number, including area code (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per ShareMDGLThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit Number Description
99.1Press Release Dated August 5, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL Document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MADRIGAL PHARMACEUTICALS, INC.
By:/s/ Mardi Dier Name: Mardi Dier Title: Executive Vice President and Chief Financial Officer Date: August 5, 2025
3
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Insider Monkey
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
📊
AI Sentiment
Positive
7/10
Compare MDGL vs Leading Stocks
See how MDGL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.